Skip to main content

LGND

Stock
Health Care
Biotechnology

Performance overview

LGND Price
Price Chart

Forward-looking statistics

Beta
0.71
Risk
42.62%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.

Company info

SectorHealth Care
IndustryBiotechnology
Employees94
Market cap$1.5B

Fundamentals

Enterprise value$2.0B
Revenue$181.5M
Revenue per employee—
Profit margin-73.07%
Debt to equity0.56

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$7.29
Dividend per share—
Revenue per share$9.73
Avg trading volume (30 day)$17M
Avg trading volume (10 day)$20M
Put-call ratio—

Macro factor sensitivity

Growth-1.9
Credit+7.4
Liquidity+1.7
Inflation-6.3
Commodities-1.8
Interest Rates-1.1

Valuation

Dividend yield0.00%
PEG Ratio19.16
Price to sales12.18
P/E Ratio19.16
Enterprise Value to Revenue10.96
Price to book2.78

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day—
Ex. dividend dayJuly 2, 2010

News

What Makes Ligand (LGND) a New Strong Buy Stock

Ligand (LGND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research (June 14, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free